Csl
CSL Limited, commonly referred to as CSL, is a global biotechnology leader headquartered in Australia. Founded in 1916, the company has evolved significantly, establishing a strong presence in key operational regions including North America, Europe, and Asia-Pacific. Specialising in the development of innovative therapies for rare and serious diseases, CSL focuses on areas such as immunology, haematology, and respiratory health. The company is renowned for its core products, including immunoglobulins and clotting factors, which are distinguished by their high quality and efficacy. CSL's commitment to research and development has positioned it as a market leader, with notable achievements such as being consistently ranked among the top biopharmaceutical companies globally. With a rich history and a dedication to improving patient outcomes, CSL continues to set benchmarks in the biotechnology industry.
DitchCarbon Score
How does Csl's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Csl's score of 31 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Csl's reported carbon emissions
In 2023, CSL Limited reported total carbon emissions of approximately 336,000,000 kg CO2e, comprising 113,000,000 kg CO2e from Scope 1 and 223,000,000 kg CO2e from Scope 2 emissions. The company has shown a commitment to reducing its carbon footprint, with a focus on near-term targets, although specific reduction targets have not been disclosed. Over the past few years, CSL's emissions have fluctuated, with 2022 emissions recorded at about 347,000,000 kg CO2e, and 2021 emissions at approximately 2,284,000,000 kg CO2e for Scope 3, alongside 324,000,000 kg CO2e for both Scope 1 and Scope 2. This indicates a significant reliance on Scope 3 emissions, which are often the largest source of emissions for companies in the pharmaceuticals and biotechnology sector. CSL has committed to near-term reduction initiatives, although it has not set a net-zero target as of now. The company continues to focus on sustainability within its operations, aligning with industry standards and practices to mitigate climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Csl is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
